ReviewFrontiers in pharmacology2026
Specialized pro-resolving mediators and cancer: news and promises from the other side of the moon.
Review in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In physiological settings, inflammation is not passively terminated but actively resolved through coordinated endogenous programs. A central component of this response is the biosynthesis of specialized pro-resolving mediators (SPMs), including lipoxins, resolvins, protectins, and maresins. These SPMs arise from polyunsaturated fatty acid precursors that are partially shared with those of classical pro-inflammatory mediators, such as prostaglandins and leukotrienes. Rather than broadly suppressing immunity, SPMs promote the restoration of tissue homeostasis by limiting excessive leukocyte recruitment, enhancing efferocytosis, and reprogramming inflammatory responses. Inflammation is a recognized enabler of cancer, contributing to the main hallmarks of tumor progression, such as sustained proliferative signaling, angiogenesis, and immune evasion. A chronically inflamed tumor microenvironment fosters cancer progression in a complex, tumor- and stage-specific manner. This persistent inflammatory context has supported the prescient view of tumors as "wounds that do not heal." While the pro-tumorigenic functions of inflammatory lipid mediators, such as prostaglandin E
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.